Companies with late-stage cell and gene therapies
32 companies hold rights to 28 cell and gene therapies (cell therapies, gene therapies and gene editing) that are in Phase 3, Phase 2/3 or filed for approval. Sorted by the number of such drugs, then by name. Approved drugs are not counted. The full directory, with financials, is on the companies page.
| Company | Ticker | Late-stage | Drugs (stage, indications) |
|---|---|---|---|
| REGENXBIO Inc. | RGNX | 3 | Clemidsogene lanparvovec (Phase 3, Mucopolysaccharidosis Type II); Surabgene lomparvovec (Phase 3, Age-Related Macular Degeneration); RGX-202 (Phase 2/3, Duchenne Muscular Dystrophy) |
| Nippon Shinyaku | 4516 | 2 | Clemidsogene lanparvovec (Phase 3, Mucopolysaccharidosis Type II); deramiocel (Phase 3, Heart Failure, Duchenne Muscular Dystrophy) |
| AbbVie | ABBV | 1 | Surabgene lomparvovec (Phase 3, Age-Related Macular Degeneration) |
| AnGes | 4563 | 1 | Beperminogene perplasmid (HGF plasmid) (Phase 3, Atherosclerotic Cardiovascular Disease) |
| Artgen Biotech | ABIO | 1 | Neovasculgen (Phase 2/3, Atherosclerotic Cardiovascular Disease) |
| AstraZeneca | AZN | 1 | AZD0120 (Phase 3, Multiple Myeloma, Systemic Lupus Erythematosus, Rheumatoid Arthritis and more) |
| Bayer | BAYN | 1 | Bemdaneprocel (MSK-DA01) (Phase 3, Parkinson's Disease) |
| Beijing Northland Biotech | — | 1 | NL003 (Phase 3, Atherosclerotic Cardiovascular Disease) |
| BioCardia | BCDA | 1 | CardiAMP (Phase 3, Heart Failure, Ischemic Heart Failure) |
| BlueRock Therapeutics | — | 1 | Bemdaneprocel (MSK-DA01) (Phase 3, Parkinson's Disease) |
| Bristol-Myers Squibb | BMY | 1 | Arlocabtagene autoleucel (Phase 3, Multiple Myeloma) |
| Candel Therapeutics, Inc. | CADL | 1 | Aglatimagene Besadenovec (Phase 3, Non-Small Cell Lung Cancer) |
| Capricor Therapeutics | CAPR | 1 | deramiocel (Phase 3, Heart Failure, Duchenne Muscular Dystrophy) |
| Cartesian Therapeutics, Inc. | RNAC | 1 | Descartes-08 (Phase 3, Myasthenia Gravis, Dermatomyositis) |
| EHL Bio | — | 1 | ADSTEM (Phase 3, Atopic Dermatitis) |
| Eli Lilly | LLY | 1 | Ixoberogene soroparvovec (Phase 3, Wet Age-Related Macular Degeneration) |
| Gilead Sciences | GILD | 1 | Anitocabtagene autoleucel (Phase 3, Multiple Myeloma) |
| Grünenthal GmbH | — | 1 | rexlemestrocel-L (Phase 3, Heart Failure, Chronic Low Back Pain) |
| HELP Therapeutics | — | 1 | HiCM-188 (allogeneic iPSC-cardiomyocytes) (Phase 3, Heart Failure) |
| IASO Biotherapeutics | — | 1 | Equecabtagene autoleucel (Phase 3, Multiple Myeloma) |
| Jiangsu Topcel-KH Pharmaceutical | — | 1 | TH-SC01 (Phase 3, Crohn's Disease) |
| Juno Therapeutics, Inc. | — | 1 | Arlocabtagene autoleucel (Phase 3, Multiple Myeloma) |
| Lyell Immunopharma, Inc. | LYEL | 1 | Rondecabtagene autoleucel (Phase 3, Large B-Cell Lymphoma) |
| Mesoblast | MESO | 1 | rexlemestrocel-L (Phase 3, Heart Failure, Chronic Low Back Pain) |
| Opus Genetics, Inc. | IRD | 1 | OPGx-LCA5 (Phase 3, Leber Congenital Amaurosis) |
| ProKidney | PROK | 1 | Rilparencel (Phase 3, Chronic Kidney Disease) |
| Regend Therapeutics | — | 1 | REGEND001 (Phase 3, Chronic Obstructive Pulmonary Disease) |
| Regeneron Pharmaceuticals | REGN | 1 | Nexiguran ziclumeran (Phase 3, Transthyretin Amyloidosis with Cardiomyopathy) |
| Tasly Pharmaceutical Group | 600535 | 1 | rexlemestrocel-L (Phase 3, Heart Failure, Chronic Low Back Pain) |
| TScan Therapeutics, Inc. | TCRX | 1 | TSC-101 (Phase 3, Hematologic Malignancies) |
| TuHURA Biosciences | HURA | 1 | IFx-2.0 (Phase 2/3, Merkel Cell Carcinoma) |
| Vertex Pharmaceuticals | VRTX | 1 | Zimislecel (Phase 3, Type 1 Diabetes) |
Stage is the furthest stage the drug has reached in any indication. Kind follows each drug's recorded modality; a drug whose modality is not recorded is left out.